On February 16, 2022, FDA posted a compounding chance inform describing the probable challenges affiliated with at-property use of compounded ketamine nasal spray and several other adverse event stories. The February 2022 compounding threat notify also delivered specifics of Spravato, which happens to be subject matter to a Hazard Analysis and Miti